Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Pharmaceutical TechnologyAn indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer's tafamidis in frontline ATTR-CM.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology An indirect comparison highlights the potential of BridgeBio’s Attruby to best Pfizer’s tafamidis in frontline ATTR-CM. Cardiovascular Read full story Post navigation Previous: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)Next: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
